Literature DB >> 15015030

Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

P S McKinnon1, S L Davis.   

Abstract

This review outlines some of the many factors a clinician must consider when selecting an antimicrobial dosing regimen for the treatment of infection. Integration of the principles of antimicrobial pharmacology and the pharmacokinetic parameters of an individual patient provides the most comprehensive assessment of the interactions between pathogen, host, and antibiotic. For each class of agent, appreciation of the different approaches to maximize microbial killing will allow for optimal clinical efficacy and reduction in risk of development of resistance while avoiding excessive exposure and minimizing risk of toxicity. Disease states with special considerations for antimicrobial use are reviewed, as are situations in which pathophysiologic changes may alter the pharmacokinetic handling of antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015030     DOI: 10.1007/s10096-004-1107-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  133 in total

1.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Interference of dairy products with the absorption of ciprofloxacin.

Authors:  P J Neuvonen; K T Kivistö; P Lehto
Journal:  Clin Pharmacol Ther       Date:  1991-11       Impact factor: 6.875

Review 3.  Pharmacokinetics of systemically administered antibiotics in patients with thermal injury.

Authors:  B A Boucher; D A Kuhl; W L Hickerson
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

4.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

5.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 6.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

7.  Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.

Authors:  J P McCormack; J J Schentag
Journal:  Drug Intell Clin Pharm       Date:  1987-02

Review 8.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

9.  Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects.

Authors:  R L Yost; H Derendorf
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

Review 10.  Aminoglycosides: nephrotoxicity.

Authors:  M P Mingeot-Leclercq; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

View more
  20 in total

Review 1.  Pharmacologic considerations in antimicrobial therapy, with emphasis on pharmacokinetics and pharmacodynamics: reviews for the practicing clinician.

Authors:  P S McKinnon; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

2.  Widely Used Benzalkonium Chloride Disinfectants Can Promote Antibiotic Resistance.

Authors:  Minjae Kim; Michael R Weigand; Seungdae Oh; Janet K Hatt; Raj Krishnan; Ulas Tezel; Spyros G Pavlostathis; Konstantinos T Konstantinidis
Journal:  Appl Environ Microbiol       Date:  2018-08-17       Impact factor: 4.792

Review 3.  Variations in amoxicillin pharmacokinetic/pharmacodynamic parameters may explain treatment failures in acute otitis media.

Authors:  Michael E Pichichero; Michael D Reed
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  The management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes.

Authors:  Simon Matthew Graham; Adelle Fishlock; Peter Millner; Jonathan Sandoe
Journal:  Eur Spine J       Date:  2013-04-01       Impact factor: 3.134

5.  Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

Review 6.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

7.  How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?

Authors:  P Bourget; A Amin; C Dupont; M Abely; N Desmazes-Dufeu; J C Dubus; B-L Jouani; C Merlette; R Nové-Josserand; J Pages; R Panzo; F Vidal; F Voge; D Hubert
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 8.  Staphylococcus aureus biofilms: properties, regulation, and roles in human disease.

Authors:  Nathan K Archer; Mark J Mazaitis; J William Costerton; Jeff G Leid; Mary Elizabeth Powers; Mark E Shirtliff
Journal:  Virulence       Date:  2011-09-01       Impact factor: 5.882

9.  Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic fever.

Authors:  Byung-Jin Ahn; Dong-Seok Yim; Dong-Gun Lee; Jae-Cheol Kwon; Si-Hyun Kim; Su-Mi Choi
Journal:  Yonsei Med J       Date:  2011-07       Impact factor: 2.759

10.  Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.

Authors:  Elias Gebru; Joong-Su Lee; Zhi-Qiang Chang; Mi-Hyun Hwang; Henrique Cheng; Seung-Chun Park
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.